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Abstract
Introduction:  The  Sino-Nasal  Outcome  Test  22  (SNOT-22)  is  an  important  tool  in  assessing  the
quality of  life  (QoL)  of  patients  with  chronic  rhinosinusitis  with  a  validated  version  in  Brazil.  The
eosinophilic  nasal  polyposis  (ENP)  represents  most  of  the  cases  of  nasal  polyposis  (85--90%)  and
belongs to  the  group  of  chronic  rhinosinusitis.  It  is  a  chronic  inﬂammatory  disease  that  impacts
the QoL  of  patients,  not  only  causing  localized  symptoms,  but  also  resulting  in  a  general  malaise.
The standard  treatments  (corticosteroids  and  nasal  endoscopic  surgery)  lead  to  partial  control
of symptoms,  but  relapses  are  frequent.  Macrolide  acting  as  an  immunomodulator  is  a  promising
tool for  more  effective  control  of  this  disease.  Studies  are  still  lacking  to  assess  the  real  impact
on the  QoL  in  patients  treated  with  macrolides.
Objective:  To  evaluate  the  improvement  of  QL,  evaluated  using  SNOT-22,  in  patients  with  PNSE
treated with  immunomodulatory  dose  azithromycin.
 Please cite this article as: Oliveira IS, Crosara PFTB, Cassali GD, Reis DC, Resende C, Nunes FB, et al. Evaluation of the improvement of
uality of life with Azithromycin in the treatment of eosinophilic nasal polyposis. Braz J Otorhinolaryngol. 2016;82:198--202.
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Methods:  This  is  a  paired  experimental  study  in  patients  with  ENP.  Comparison  of  pre-treatment
and post-treatment  with  azithromycin  was  performed.  Patients  completed  the  SNOT-22  ques-
tionnaire  before  the  start  of  treatment  and  returned  for  evaluation  after  eight  weeks  of
treatment.  Azithromycin  was  prescribed  at  a  dose  of  500  mg,  orally,  three  times  a  week,  for  8
weeks.
Results: SNOT-22  score  decreased  20.3  points  on  average.  There  was  a  signiﬁcant  decrease  in
the SNOT-22  (difference  greater  than  14  points)  in  19  patients  (57.6%).  There  was  no  signiﬁcant
difference  in  improvement  in  SNOT  in  subgroups  with  or  without  asthma/aspirin  intolerance.
Conclusion:  Azithromycin  resulted  in  signiﬁcant  improvement  of  QoL,  assessed  by  SNOT-22,  in
the studied  population.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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Avaliac¸ão  da  melhora  da  qualidade  de  vida  com  o  uso  de  Azitromicina  no  tratamento
da  polipose  nasossinusal  eosinofílica
Resumo
Introduc¸ão: O  Sino-Nasal  Outcome  Test  22  (SNOT-22)  está  entre  os  principais  instrumentos  na
avaliac¸ão da  qualidade  de  vida  dos  pacientes  com  rinossinusite  crônica,  com  versão  validada  no
Brasil. A  polipose  nasossinusal  eosinofílica  (PNSE)  representa  a  maioria  dos  casos  de  polipose
nasossinusal  (85%  a  90%)  e  pertence  ao  grande  grupo  das  rinossinusites  crônicas.  É  uma  doenc¸a
inﬂamatória  crônica  que  impacta  sobremaneira  a  qualidade  de  vida  (QV)  dos  pacientes,  não  só
pelos sintomas  locais,  mas  também  por  resultarem  em  um  quadro  de  mal-estar  geral.  Os  trata-
mentos padronizados  (corticosteroides  e  cirurgia  endoscópica  nasal)  levam  ao  controle  parcial
dos sintomas  e  as  recidivas  são  frequentes.  Os  macrolídeos  usados  como  imunomoduladores  são
uma promissora  ferramenta  para  um  controle  mais  eﬁcaz  dessa  doenc¸a.  Ainda  faltam  estudos
para avaliar  o  real  impacto  na  QV  dos  pacientes  tratados  com  macrolídeos.
Objetivo:  Avaliar  a  melhora  da  QV  do  paciente  portador  de  PNSE  tratado  com  azitromicina  em
dose imunomoduladora  baseando-se  questionário  SNOT-22.
Método:  Trata-se  de  estudo  experimental  autopareado  em  pacientes  com  PNSE.  Foi  realizada
a comparac¸ão  dos  pacientes  pré-tratamento  e  pós-tratamento  com  azitromicina.  Os  pacientes
preencheram  o  questionário  SNOT-22  antes  do  início  do  tratamento  e  no  retorno  após  as  oito
semanas de  tratamento.  Foi  prescrita  azitromicina  na  dose  de  500  mg,  VO,  três  vezes  por
semana, durante  8  semanas.
Resultados:  O  valor  do  índice  SNOT-22  dos  pacientes  reduziu  20,3  pontos,  em  média.  Houve
diminuic¸ão signiﬁcativa  do  SNOT-22  (diferenc¸a  maior  que  14  pontos)  em  19  pacientes  (57,6%).
Não houve  uma  diferenc¸a  signiﬁcativa  na  melhora  do  SNOT  nos  subgrupos  com  ou  sem
asma/intolerância  à  aspirina.
Conclusão:  A  azitromicina  resultou  em  melhora  signiﬁcativa  da  QV,  avaliada  pelo  questionário
SNOT-22, na  populac¸ão  estudada.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este  é  um  artigo  Open  Access  sob  a  licença  de  CC  BY
(http://creativecommons.org/licenses/by/4.0/).
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Quality  of  life  (QoL)  is  a  very  important  consideration  in
assessing  the  severity  of  nasal  disease,  clinical  effectiveness
of  treatments  used  and  quality  of  care  of  these  patients.1
Questionnaires  for  QoL  have  been  frequently  used  in  clini-
cal  trials  to  determine  the  impact  caused  by  an  intervention
in  certain  diseases,  or  to  evaluate  the  results  of  health
services.2
The  Sino-Nasal  Outcome  Test  22  (SNOT-22)  is  one  of  the
main  instruments  in  assessing  QoL  of  patients  with  chronic
p
e
mhinosinusitis,  with  a  Brazilian-validated  version.2 It  is  a  spe-
iﬁc  questionnaire  for  QoL  analysis  in  nasosinusal  diseases.
ith  this  tool,  evaluations  of  nasal,  paranasal,  psychological
nd  sleep-related  symptoms  are  carried  out.1
Eosinophilic  nasal  polyposis  (ENP),  is  found  in  approx-
mately  85--90%  all  cases  of  sinonasal  polyposis.3--5 This
isease  belongs  to  the  heterogeneous  group  of  chronic  rhi-
osinusitides  (CRS),  with  involvement  of  nasal  mucosa  and
aranasal  sinuses,  being  characterized  by  the  presence  of
dematous  formations  resulting  from  prolapse  of  the  lining
ucosa.6
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ENP  is  the  end  result  of  a  chronic  inﬂammation  of  nasal
ucosa  and  paranasal  sinuses  that  greatly  impacts  QoL
f  patients,  not  only  by  local  symptoms  (headache,  nasal
ongestion  and  chronic  secretion),  but  also  by  resulting  in  a
oor  general  status.7,8
Currently,  corticosteroids  are  considered  the  main  thera-
eutic  option  for  ENP.9 However,  the  high  rates  of  recurrence
f  the  disease,  low  response  maintenance,  persistence  of
ymptoms  and  side  effects  of  systemic  corticosteroids  are
he  main  challenges  to  its  treatment.7,10,11 Sinus  endoscopic
urgery  is  reserved  for  cases  of  clinical  treatment  failure,
ut  even  in  experienced  hands  this  technique  may  have
ecurrence  rates  ranging  from  35  to  50%  of  cases.7,12--14 In
linical  practice,  most  patients  need  both  treatments  with-
ut,  however,  achieving  satisfactory  results  in  controlling
he  symptoms.15
The  search  for  other  therapeutic  options  led  to  the  study
f  drugs  that  can  act  to  control  the  inﬂammatory  process,
inimizing  those  so-feared  side  effects  from  chronic  use
f  corticosteroids,  in  addition  to  maintaining  a  prolonged
herapeutic  response.  In  this  context,  macrolides  stand
ut.
Azithromycin  is  a  member  of  the  cyclic-structure
acrolide  class  with  15  elements.16 It  is  the  only  agent,
mong  macrolides,  which  does  not  inhibit  the  activity  of
ytochrome  P450  (involved  in  the  metabolism  of  many  drugs
nd  in  cholesterol  and  steroid  synthesis).17 Azithromycin  is
 well-tolerated  agent  and,  according  to  the  European  Posi-
ion  Paper  on  Rhinosinusitis  and  Nasal  Polyps  2012,18 the
ong-term  safety  of  treatment  with  macrolides  in  chronic
hinosinusitis  is  already  established.
The  aim  of  this  study  was  to  assess  improvement  of  QoL  in
atients  with  ENP  treated  with  an  immunomodulatory  dose
f  azithromycin  based  on  the  application  of  SNOT-22.
ethods
his  study  was  submitted  and  approved  by  the  Ethics
ommittee  (opinion  approval  no.  234,835).  Patients  were
nformed  about  the  study  and  its  objectives  and  were
equested,  after  assisted  reading  and  orientation,  to  sign
 post-informed  consent  form.
The  sample  consisted  of  patients  with  ENP  aged  18--60
ears  and  referred  by  the  Brazilian  Uniﬁed  Health  System
SUS)  to  perform  surgical  treatment  in  the  institution.  Such
atients,  with  an  established  clinical,  endoscopic  and  radio-
ogical  diagnosis  of  PNS,  had  been  treated  by  an  optimized
tandard  drug  therapy  with  no  appropriate  response.
The  sample  size  required  for  the  study  was  estimated
sing  a  signiﬁcance  level  of  5%  (˛  =  0.05)  and  statistical
ower  of  80%  (ˇ  =  0.2).  To  detect  a  difference  of  14  units
n  the  evaluation  with  SNOT-22  questionnaire  and  assuming
hat  the  standard  deviation  of  the  results  of  this  assessment
s  <28  (/ε  =  2),  the  sample  size  required  is  32,  based  on
he  formula  n  = (2[z  (˛/2)  +  z(ˇ)])  *  (/ε)2.  Similar  studies
nvolved  20  patients.19,20
In  the  screening  procedure,  the  patients  underwent  a  full
NT  clinical  exam  with  special  attention  to  the  nasal  area.
he  nasal  cavity  was  explored  via  anterior  rhinoscopy  and
asoﬁbriolaryngoscopy.  PNS  was  staged  according  to  Sousa
t  al.21 A  3.2-mm  diameter  ﬂexible  nasoﬁbroscope  MACHIDA
t
d
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NT  IIIPTM was  used.  All  patients  underwent  biopsy  of  nasal
olyps  to  conﬁrm  a  diagnosis  of  eosinophilia.
Patients  who  met  the  following  criteria  were  selected.
Inclusion  criteria:  Patients  with  eosinophilic  nasal  poly-
posis  with  eosinophil  percentage  ≥20%  and  who,  at  their
clinical  and  endoscopic  examination,  showed  no  evidence
of  active  nasal  infection  (e.g.,  purulent  discharge  in  nasal
cavity).
Exclusion  criteria:  Patients  with  non-eosinophilic  poly-
posis  such  as  cystic  ﬁbrosis,  Kartagener  syndrome,
antrochoanal  polyps  and/or  eosinophilic  nasal  polyposis  in
the  presence  of  infection;  patients  who  used  oral  or  inhaled
corticoids  or  antihistamines  or  bronchodilators  in  a  period
of  30  days  preceding  the  beginning  of  the  study  or  at  any
time  during  the  study  period;  patients  with  established
cardiovascular  and/or  liver  disease  and  patients  with  an
abnormal  electrocardiogram  (e.g.,  QT  prolongation).
eneral  design  of  the  study
his  is  a  self-paired  experimental  study  in  patients  with
NP.  A  speciﬁc  questionnaire  was  applied  before  and  after
reatment  with  azithromycin,  with  the  aim  to  compare
ssessments  of  QoL.
Further  tests  for  preparation  of  the  surgical  procedure
ere  requested:  glutamic  oxaloacetic  transaminase  (GOT),
lutamic  pyruvic  transaminase  (SGPT)  and  alkaline  phos-
hatase  (AP).
Then,  AZITM (500-mg  coated  tablets  of  azithromycin  dihy-
rate,  Reg  MS:  No.  1.3569.0011,  EMS  S/A,  Hortolandia,  SP),  1
ablet  (500  mg)  PO  3×/week  (Mondays,  Wednesdays  and  Fri-
ays)  for  eight  weeks  was  prescribed.  In  the  ninth  week,  the
atient  returned  to  the  clinic  for  further  clinical  evaluation
nd  for  completing  a  new  SNOT-22  questionnaire.
ariable  analyzed
NOT-22  was  translated  and  adapted  to  the  Portuguese  lan-
uage  in  2011.2 It  consists  of  22  questions/symptoms  that
he  patient  can  sort  from  zero  (no  problem)  to  ﬁve  (worst
roblem  possible).  The  patient  was  advised  to  answer  the
uestions  based  on  his/her  symptoms  in  the  two  previous
eeks.  The  sum  of  the  values  can  range  from  0  to  110
oints  and,  the  higher  this  value,  the  more  symptomatic  the
atient.
With  the  help  of  a  researcher,  the  participants  completed
he  SNOT-22  questionnaire  before  stating  the  treatment  and
n  their  return  after  eight  weeks  of  therapy.
tatistical  analysis
aired  t test  was  used  to  compare  pre-  and  post-treatment
eans.  The  conﬁdence  intervals  for  the  percentages  were
btained  by  the  Clopper--Pearson  method.  The  frequency  of
inary  variables  in  different  subgroups  was  compared  using
he  chi-squared  test.
Statistical  analyses  were  performed  using  the  public-
omain  software  Rx64  version  2.15.2,  and  the  conclusions
rawn  from  the  results  were  obtained  considering  a
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Table  1  Post-treatment  results  of  SNOT-22.
Group  n  Mean  reduction  of  SNOT-22  Signiﬁcant  reduction  (>14)  CI  95%  (Clopper--Pearson)
Chose  surgery  11  13.6  4  (36.4%)  16.9--69.3%
Did not  choose  surgery  22  23.7  15  (68.2%)  49.8--86.1%
Total 33  20.3  19  (57.6%)  42.2--74.5%
Non-signiﬁcant difference (p = 0.17) between percentages of groups that chose/did not choose surgery.
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dsigniﬁcance  level  of  5%  and  a  95%  conﬁdence  interval.  Data
were  entered  into  the  database  developed  on  Microsoft
ExcelTM.
Results
Thirty-three  patients  completed  the  study.  The  patients’
ages  ranged  from  18  to  69  years,  with  a  mean  of  48.84  years,
with  21  women  (63.6%)  and  12  men.  Seventeen  patients
(51.5%)  had  asthma  and/or  aspirin  intolerance.  Only  one
female  patient  reported  side  effects  (heartburn/burning)
during  the  use  of  medication;  however,  there  was  no  need
to  discontinue  treatment.
At  the  end  of  the  study,  22  patients  reported  good
symptom  control,  and  chose  not  to  undergo  surgical  treat-
ment.  These  patients  were  kept  in  clinical  follow-up.  Eleven
patients  chose  to  undergo  a  surgical  procedure,  because
they  did  not  feel  fully  satisﬁed  with  their  post-treatment
results.
The  normal  threshold  for  the  Brazilian  version  of  SNOT-
22  is  10  points,  and  a  variation  >14  points  between  SNOT-22
scores  of  the  same  patient  is  considered  as  signiﬁcant.2
Thus,  in  the  present  study,  we  had  one  pre-treatment
patient  and  4  post-treatment  patients  with  a  normal  SNOT-
22  score.  Only  two  patients  showed  a  worse  result  in
SNOT-22  (increases  of  1  and  4  points,  values  considered
not  signiﬁcant  according  to  the  literature).  The  SNOT-22
score  of  all  patients  decreased  by  a  mean  of  20.3  points.
Nineteen  patients  (57.6%)  showed  a  reduction  >14  points,
considered  as  signiﬁcant  (p  <  0.01).  It  is  estimated  that,  in
general,  42--74%  of  patients  show  improvement  in  their  post-
treatment  SNOT-22  evaluation.  Table  1  lists  an  analysis  of
the  results  of  SNOT-22.
The  response  to  the  treatment  was  different  in  subgroups
with/without  asthma  or  aspirin  intolerance.  A  signiﬁcant
difference  in  reduction  of  SNOT-22  score  between  groups
with  or  without  asthma/aspirin  intolerance  was  not  found
(Table  2).
Table  2  Subgroup  analysis  with/without  asthma  or  aspirin
intolerance.
Criterion  Asthma/aspirin  intolerance
Yes  (17)  No  (16)  p-Value
SNOT-22  reduction  >14  8  (47.1%)  11  (68.8%)  0.364
n
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he  description  of  QoL  is  seen  as  an  unique  and  personal
xperience,  which  reﬂects  not  only  the  health  status,  but
lso  other  factors  and  circumstances  of  the  patient’s  life.2
ccording  to  this  deﬁnition,  the  comparison  between  values
f  SNOT-22  should  not  be  performed  among  patients,  but
ne  can  compare  the  change  that  occurs  before  and  after
ny  intervention  in  a  given  patient.
In  patients  analyzed  in  the  present  study,  we  observed
 signiﬁcant  improvement  in  QoL  assessed  by  SNOT-22
fter  treatment  with  azithromycin  for  2  months  (8  weeks).
hese  ﬁndings  corroborate  previous  studies,21--24 but  for
he  ﬁrst  time  a  study  of  a  speciﬁc  and  well  determined
roup  was  carried  out.  No  signiﬁcant  difference  between
roups  with  and  without  asthma/aspirin  intolerance  was
oted.
Interestingly,  the  improvement  in  SNOT-22  scores  did  not
ffect  signiﬁcantly  the  patient’s  decision  as  to  whether  or
ot  to  undergo  surgery,  since  the  decrease  in  the  question-
aire  score  was  not  signiﬁcantly  different  (p  =  0.17)  for  those
roups  who  have  chosen  or  declined  surgery.
The  SNOT-22  questionnaire  has  the  advantage  of  combin-
ng  speciﬁc  issues  of  nasosinusal  disease  with  general  health
ssues,  which  can  be  evaluated  separately  or  together,
efore  or  after  treatment.2 In  line  with  the  authors  of  the
ranslation,  cultural  adaptation  and  validation  of  the  SNOT-
2  questionnaire  into  Portuguese,  we  choose  to  standardize
he  form  of  application,  performing  the  reading  of  the  ques-
ionnaire  for  our  patients,  given  the  difﬁculties  of  reading
nd  text  comprehension  by  the  population  served  by  our
ervice.
Clinical  interpretability  is  the  main  challenge  for
esearchers  interested  in  measuring  QoL  questionnaires,  as
hese  tools  do  not  produce  intuitively  meaningful  data,  thus
aking  it  difﬁcult  to  interpret  the  clinical  signiﬁcance  of  the
ifferences  among  groups  of  individuals.2
In  the  last  edition  of  the  European  Position  Paper  on  Rhi-
osinusitis  and  Nasal  Polyps  2012,18 studies  that  evaluated
he  effect  of  macrolides  in  nasosinusal  polyposis  are  cited.
 moderate  effect  on  reducing  the  size  of  the  polyps  was
dentiﬁed,  and  this  effect  has  proved  more  longstanding
han  that  achieved  with  the  use  of  systemic  corticosteroids.
owever,  these  studies  also  failed  to  assess  QoL  and  clinical
eneﬁts  for  patients.
In  the  present  study,  we  observed  an  improvement  of
oL  measured  by  the  SNOT-22  questionnaire  after  treat-
ent  with  azithromycin.  Thus,  we  have  demonstrated  that
he  treatment  with  macrolides  can  result  in  real  beneﬁt  to
hese  patients.
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ENP  patients,  particularly  those  with  asthma  and  aspirin
ntolerance,  present  a  difﬁcult-to-control  disease,  requiring
xtensive  surgery  in  most  cases.  Furthermore,  in  many  cases
hese  patients  are  subjected  to  several  operations  through-
ut  their  life.  In  the  authors’  opinion,  any  adjuvant  clinical
reatment  that  helps  control  symptoms  and  improving  QoL
f  these  patients,  without  causing  signiﬁcant  additional  side
ffects,  should  be  considered.
onclusion
reatment  with  azithromycin  500  mg,  3×/week  for  8  weeks,
n  the  population  studied  showed  signiﬁcant  improvement
n  QoL  as  assessed  by  the  SNOT-22  questionnaire,  with  no
ifference  in  improvement  between  groups  with  and  without
sthma/aspirin  intolerance.
onﬂicts of interest
he  authors  declare  no  conﬂicts  of  interest.
eferences
1. Marambaia PP, Lima MG, Santos KP, Gomes AM, de Sousa MM,
Marques ME. Evaluation of the quality of life of patients with
chronic rhinosinusitis by means of the SNOT-22 questionnaire.
Braz J Otorhinolaryngol. 2013;79:54--8.
2. Kosugi EM, Chen VG, Fonseca VM, Cursino MM, Mendes Neto
JA, Gregório LC. Translation, cross-cultural adaptation and
validation of SinoNasal Outcome Test (SNOT): 22 to Brazilian
Portuguese. Braz J Otorhinolaryngol. 2011;77:663--9.
3. Valera FCP, Nakanishi M, Fernandes AM. Polipose nasossinusal.
In: Caldas Neto S, Mello Júnior JF, Martins RHG, Costa SS, edit-
ors. Tratado de Otorrinolaringologia. 2nd ed. Roca: São Paulo;
2003. p. 111--20.
4. Anjos CP, Vasconcelos AC, Crosara PF, Anjos GC, Becker CG,
Guimarães RE. Apoptosis in eosinophilic nasal polyps treated
in vitro with mitomycin C. Braz J Otorhinolaryngol. 2012;
78:32--7.
5. Pawankar R. Nasal polyposis: an update: editorial review. Curr
Opin Allergy Clin Immunol. 2003;3:1--6.
6. Fonseca AL, Arrobas AM. Allergic inﬂammatory diseases of the
upper airways and their impact on asthma -- following on from
a case report. Rev Port Pneumol. 2006;12:563--79.
7. Hoseini SM, Saedi B, Aghazadeh K. Meticulous endoscopic sinus
surgery to prevent recurrence of massive nasal polyposis. J
Laryngol Otol. 2012;126:789--94.
8. Cervin A. The anti-inﬂammatory effect of erythromycin and
its derivatives, with special reference to nasal polyposis and
chronic sinusitis. Acta Otolaryngol. 2001;121:83--92.
9. Saunders MW, Wheatley AH, George SJ, Lai T, Birchall MA. Do
corticosteroids induce apoptosis in nasal polyp inﬂammatory
2Oliveira  IS  et  al.
cells? In vivo and in vitro studies. Laryngoscope. 1999;109:
785--90.
0. Sieskiewicz A, Olszewska E, Rogowski M, Grycz E. Preoperative
corticosteroid oral therapy and intraoperative bleeding during
functional endoscopic sinus surgery in patients with severe nasal
polyposis: a preliminary investigation. Ann Otol Rhinol Laryngol.
2006;115:490--4.
1. Sheth A, Reddymasu S, Jackson R. Worsening of asthma with
systemic corticosteroids. A case report and review of literature.
J Gen Intern Med. 2006;21:C11--3.
2. Larsen K, Tos M. A long-term follow-up study of nasal polyp
patients after simple polypectomies. Eur Arch Otorhinolaryngol.
1997;254:S85--8.
3. Morley AD, Sharp HR. A review of sinonasal outcome scoring
systems -- which is best. Clin Otolaryngol. 2006;31:103--9.
4. Dabirmoghaddam P, Mehdizadeh Seraj J, Bastaninejad S,
Meighani A, Mokhtari Z. The efﬁcacy of clarithromycin in
patients with severe nasal polyposis. Acta Med Iran. 2013;51:
359--64.
5. Pynnonen MA, Venkatraman G, Davis GE. Macrolide therapy for
chronic rhinosinusitis: a meta-analysis. Otolaryngol Head Neck
Surg. 2013;148:366--73.
6. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG.
Immunomodulatory effects of macrolide antibiotics -- part 1:
biological mechanisms. Respiration. 2011;8:67--74.
7. Cervin A, Wallwork B. Efﬁcacy and safety of long-term antibi-
otics (macrolides) for the treatment of chronic rhinosinusitis.
Curr Allergy Asthma Rep. 2014;14:416.
8. Fokkens WJ,  Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F,
et al. European position paper on rhinosinusitis and nasal polyps
2012. Rhinol Suppl. 2012:1--298.
9. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide
treatment decreased the size of nasal polyps and IL-8 levels in
nasal lavage. Am J Rhinol. 2000;14:143--8.
0. Ichimura K, Shimazaki Y, Ishibashi T, Higo R. Effect of new
macrolide roxithromycin upon nasal polyps associated with
chronic sinusitis. Auris Nasus Larynx. 1996;23:48--56.
1. Zeng M, Long XB, Cui YH, Liu Z. Comparison of efﬁcacy of
mometasone furoate versus clarithromycin in the treatment of
chronic rhinosinusitis without nasal polyps in Chinese adults.
Am J Rhinol Allergy. 2011;25:e203--7.
2. Ragab SM, Lund VJ, Scadding G. Evaluation of the medical
and surgical treatment of chronic rhinosinusitis: a prospec-
tive, randomised, controlled trial. Laryngoscope. 2004;114:
923--30.
3. Peric´ A, Vojvodic´ D, Matkovic´-Jozˇin S. Effect of long-term,
low-dose clarithromycin on T helper 2 cytokines, eosinophilic
cationic protein and the ‘regulated on activation, normal T
cell expressed and secreted’ chemokine in the nasal secreti-
ons of patients with nasal polyposis. J Laryngol Otol. 2012;126:
495--502.4. Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin
A. A double-blind, randomized, placebo-controlled trial of
macrolide in the treatment of chronic rhinosinusitis. Laryngo-
scope. 2006;116:189--93.
